Mateusz Legut – VJRegenMed

Applying CRISPR-Cas technology in advancing autologous T-cell therapies

Simon Ng — Mon, 04 Apr 2022 09:59:20 +0000

Crispr-Cas9 technology as a gene editing tool has enabled the knockout of various inhibitory and endogenous T-cell receptors in the allogeneic setting. Mateusz Legut, PhD, New York Genome Center, New York, NY, describes issues with using Crispr-Cas9 in developing autologous T-cell therapies, including various editing efficiencies, off-targets and chromosomal abnormalities. Dr Legut additionally highlights research using lentiviral vector-mediated overexpression to screen the genome for novel genes that are potentially beneficial for T-cell therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.”

Development and applications of OverCITE-seq

Simon Ng — Mon, 04 Apr 2022 09:59:19 +0000

Mateusz Legut, PhD, New York Genome Center, New York, NY, provides an overview of the single-cell genomics method OverCITE-seq and its role in improving next-generation T cell therapies. Initial iterations of single-cell phenotyping technology came in the form CITE-seq, which enabled simultaneous RNA sequencing and measurement of surface protein levels, as well as ECCITE-seq, which utilizes CRISPR screens to assess changes in the transcriptome. OverCITE-seq, the third generation of single-cell genomics technology, measures levels of overexpressed genes and their effect on T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Overexpression of the LBTR gene to optimize T cell proliferation

Simon Ng — Thu, 31 Mar 2022 17:49:28 +0000

Mateusz Legut, PhD, New York Genome Center, New York, NY, discusses strategies to improve the efficacy of T-cells in adoptive cell therapies. Certain genes that are not typically expressed in T-cells such as the lymphotoxin beta receptor (LTBR) gene were identified via CRISPR-based analysis of the whole human genome. Overexpression of the gene led to improved cell quality without affecting functionality of the T-cells and Dr Legut emphasizes that any new genes utilized should not increase toxicity of the therapy in a clinical setting. Promising T-cell therapies with overexpressed, beneficial genes will also potentially be assessed in patients with relapsed/refractory B-cell malignancies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.